Develops first-in-class oncology therapies aimed at overcoming tumor immune evasion and drug resistance. Plans to monetize its pipeline through commercialization and/or out-licensing partnerships.
Geographic Exposure
Not disclosed
Geographic data unavailable
Revenue Drivers
Out-licensing and commercialization proceeds
Partnering to commercialize pipeline candidates via licenses and collaborations.
PERIPHERAL0%
End Markets
Pharmaceutical and biotechnology partners/licensees
Hospitals and oncology clinics (clinical trial sites)
Oncology physicians and investigators
Cancer patients (via approved therapies, if commercialized)
Specializations
Tumor microenvironment (TME) immuno-oncologyCEACAM1 immune-checkpoint blockade antibodiesDual-pathway inhibition (IRS1/2 and STAT3)Conditionally activated tri-specific antibodies (Tribody)Biomarker-enriched clinical trial design (CEACAM1, MPO, NETs)CRO-managed preclinical and clinical studies+2 more
Activities
Drug discovery and preclinical research
Clinical trial execution and management
CMC development and regulatory submissions
In-licensing/acquisition of therapeutic candidates and IP portfolio development
